The CAR-T First-Mover Advantage: Reality or Myth?

Posted by Sharon Karlsberg on Mar 12, 2019 8:00:00 AM

Robert Rovner co-wrote this blog post with Sharon Karlsberg. This article originally appeared in the January 2019 issue of OBR Green.

The “first-mover advantage” is something we’ve come to expect in the commercial world. The first to innovate and come to market usually reaps the greatest rewards, right? Facebook, Uber and Google improved on technology brought to market by actual first-movers MySpace, Sidecar and AltaVista, but then transcended them by addressing their weaknesses.


>
Read More

CAR-T Therapies: Improving on Today’s Reality and Planning for Tomorrow’s Innovation

Posted by Sharon Karlsberg on Jul 5, 2018 8:00:00 AM

Katie Blodgett and Robert Rovner co-authored this post with Sharon Karlsberg. 

Adoptive cell immunotherapy got top billing at this year’s American Society of Clinical Oncology (ASCO) meeting with its designation as the 2018 clinical cancer “Advance of the Year,” and for good reason. The first generation of chimeric antigen receptor T-cell (CAR-T) therapies, set in motion with the late 2017 approvals of Kymriah (Novartis) and Yescarta (Kite, a Gilead company), are among the most anticipated cancer breakthroughs to date.


>
Read More

Beyond PD-L1: In Search of Better Biomarkers

Posted by Sharon Karlsberg on Jul 14, 2017 8:00:00 AM

Tyler Vogt co-wrote this blog post with Sharon Karlsberg. 

Since their first approval in 2014, PD-L1 and PD-1 checkpoint inhibitors have become the backbone therapy in multiple tumor types: melanoma, bladder cancer and non-small-cell lung cancer (NSCLC). Although only 20 to 35% of patients respond to these therapies, approvals in melanoma, bladder cancer and second-line lung cancer didn’t require an associated diagnostic test for PD-L1 status. Until the failure of BMS’s CheckMate-026 trial in first-line NSCLC, oncologists were asking the question, “Should I test for PD-L1?”


>
Read More